Tempus expands Merck and Moderna collaboration to commercialize cancer vaccine Intismeran Autogene

Tempus expanded its multi-year collaboration with Merck and Moderna to support potential commercialization of the cancer vaccine Intismeran Autogene, with sequencing and sample logistics tied to each patient as Tempus moves into therapy design and manufacturing. Terms were not disclosed.

Detected & updated continuously · Source: Nebula